Ibex’s Galen Prostate Becomes First Standalone AI-Powered Cancer Diagnostics Solution to Obtain CE Mark Under the IVDR

Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics announced that Galen Prostate is now CE marked under the In Vitro Diagnostic Medical Devices Regulation (IVDR) for supporting pathologists in primary diagnosis of prostate biopsies. Galen Prostate is the first standalone AI-based cancer diagnostics product of its kind certified under the IVDR.

Recommended AI News: Edgemesh Receives Verification from the Trustworthy Accountability Group (TAG)  

IVDR is the new regulatory standard set by the European Union, replacing the previous In Vitro Diagnostic Medical Device Directive (IVDD). The new regulation sets a new bar for product performance and clinical validation, as well as post marketing surveillance. Galen Prostate received its IVDR CE certificate following a rigorous review demonstrating the quality of the product and its meticulous development process, safety, and performance. During 2023, Ibex plans to migrate additional products, including its Galen Breast and Galen Gastric solutions, under the IVDR certificate.

“Ibex continues to maintain the highest possible standards for its products, bringing cutting-edge computational solutions to improve outcomes of cancer care,” said Dr. Yael Liebes-Peer, Head of Regulatory Affairs and Quality Assurance at Ibex Medical Analytics. “Dedicated to our mission of providing every patient with an accurate, timely and personalized cancer diagnosis, we are proud to provide the market’s first IVDR-certified product, elevating the quality of diagnosis for patients, pathologists and laboratories.”

Recommended AI News: Sapia.AI Launches Regional Data Hosting Capabilities

To help improve the quality of cancer diagnosis, increase productivity and optimize pathology workflows, Galen Prostate uses AI to analyze biopsies ahead of pathologists’ review, providing them with diagnostic insights to guide their diagnosis. Galen Prostate’s algorithms were trained on large datasets from multiple pathology institutes around the world, enriched with rare prostatic malignancies. Galen helps pathologists diagnose cancer, provides additional insights, including a Gleason score, tumor size and associated morphologies for each cancer slide, and offers decision support tools to help accelerate diagnostic turnaround and reduce subjectivity.

Recommended AI News: Help Organizations to Mitigate Risk in Microsoft 365 with ‘Vectra Protect’

[To share your insights with us, please write to sghosh@martechseries.com]